AroCell Q4: Steady operations - Redeye

Redeye notes a quarter showing continuing sales growth for AroCell with good cost control. We slightly up our sales estimate for 2023e and lower our WACC following a review or Redeye Quality Rating, resulting in upwards changes to our fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/884264/arocell-q4-steady-operations?utm_source=finwire&utm_medium=RSS